Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparison of EGFR and KRAS mutations in primary and unpaired metastatic lung adenocarcinoma with potential chemotherapy effect.

Human pathology - 1 Jul 2013

Munfus-McCray Delicia, Cui Min, Zhang Zhen, Gabrielson Edward, Askin Frederic, Li Qing Kay

Abstract excerpt

Several recent studies have suggested that EGFR and KRAS mutations may be different in primary and metastatic tumors. It is also not well studied whether or not conventional chemotherapy has any effect on EGFR or KRAS mutations. In this study, we compared EGFR and KRAS mutations in primary and un...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Antineoplastic Agents
Share to DNA, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Source

Identifiers

PMID: 23337026
DOI: 10.1016/j.humpath.2012.10.016

Genes

EGFR
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23337026-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Comparison of EGFR and KRAS mutations in primary and unpaired metastatic lung adenocarcinoma with potential chemotherapy effect.PMID 23337026Read ↗

EGFR and KRAS mutations in metastatic lung adenocarcinomas.Semantic proximity Read ↗

Meta-analysis of epidermal growth factor receptor and KRAS gene status between primary and corresponding metastatic tumours of non-small cell lung cancer.Semantic proximity Read ↗

A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases.Semantic proximity Read ↗

[Comparison of EGFR mutation status in paired pre- and post-chemotherapy serum for advanced pulmonary adenocarcinoma].Semantic proximity Read ↗

[Comparison of EGFR and KRAS status between primary non-small cell lung cancer and corresponding metastases: a systematic review and meta-analysis].Semantic proximity Read ↗

The efficacy of first-line chemotherapy is associated with KRAS mutation status in patients with advanced non-small cell lung cancer: a meta-analysis.Semantic proximity Read ↗

Efficacy Differences of First-line EGFR-TKIs Alone vs. in Combination with Chemotherapy in Advanced Lung Adenocarcinoma Patients with Sensitive EGFR Mutation and Concomitant Non-EGFR Genetic Alteration(s)Semantic proximity Read ↗

Comparison of clinical outcome after first-line platinum-based chemotherapy in different types of KRAS mutated advanced non-small-cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.